In this issue:
- CAR T-cells vs. bispecific antibodies for relapsed/ refractory DLBCL
- Asciminib in newly diagnosed CML
- 7-year outcomes of venetoclax-ibrutinib in mantle-cell lymphoma
- Outcomes in AML responders after stopping venetoclax azacitidine
- Nivolumab-AVD in advanced-stage classic Hodgkin lymphoma
- Significance of MRD in Ph+ ALL
- Ixazomib-pomalidomide dexamethasone for lenalidomide-refractory MM
- Outcomes in pregnancy associated haematological malignancies
- MRD after autologous SCT and lenalidomide maintenance for MM: long-term OS
- Curative strategy for high risk smouldering myeloma
Please login below to download this issue (PDF)